MedPath

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

Conditions
Antibody-mediated Rejection
Registration Number
NCT03430414
Lead Sponsor
Thomas Mueller
Brief Summary

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological characteristics such as creatinine, proteinuria and Banff-classification. Twenty-five patients will be selected each in the therapy-responder and non-responder group. Their stored Formalin Fixed Paraffin Embedded (FFPE) biopsies will be (re)-classified according to the most recent Banff classification. Using Nanostring Technology the gene transcription of therapy-responders versus non-responders will be analyzed and compared to serological and clinical parameters.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Kidney transplant patients at the University Hospital of Zurich between 01.01.2008 - 31.12.2016 with histologically suspected or confirmed ABMR
  • Written consent for further use of data for research purposes
Exclusion Criteria
  • Age at transplantation < 18 years
  • Combined organ transplantation (incl. Kidney-Pancreas, Kidney-Liver, Kidney-Heart)
  • Incomplete laboratory and/or clinical data
  • Recurrence of the initial disease
  • Insufficient Biopsy Material for NanoString Analysis
  • Documented refusal of further data analysis for research purpose

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Transcriptome02.15.2018-03.01.2018

mRNA

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.